In the latest quarter, 4 analysts provided ratings for Celldex Therapeutics (NASDAQ:CLDX), showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
1
0
0
0
Last 30D
1
0
0
0
0
1M Ago
1
0
0
0
0
2M Ago
0
1
0
0
0
3M Ago
1
0
0
0
0
The 12-month price targets, analyzed by analysts, offer insights with an average target of $79.25, a high estimate of $90.00, and a low estimate of $67.00. This current average has increased by 10.07% from the previous average price target of $72.00.
Breaking Down Analyst Ratings: A Detailed Examination
An in-depth analysis of recent analyst actions unveils how financial experts perceive Celldex Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Joseph Pantginis
HC Wainwright & Co.
Maintains
Buy
$80.00
-
Joseph Pantginis
HC Wainwright & Co.
Maintains
Buy
$80.00
-
Kristen Kluska
Cantor Fitzgerald
Maintains
Overweight
$67.00
-
Yatin Suneja
Guggenheim
Raises
Buy
$90.00
$72.00
Key Insights:
Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Celldex Therapeutics. This information offers a snapshot of how ...Full story available on Benzinga.com
Related tickers: CLDX.
Read Full Article